However, patient-specific PHD2 haplodeficient MØs, which are essential for evaluating therapeutic effects in the context of human limb ischemia, are unavailable, restricting their real assessment for potential use in future treatments for limb ischemia. Here, EGLN1 is linked to limb ischemia.